Price Action: DCPH shares traded 3.66% lower at $16.57 on the last check Thursday. As with its Sega-based spiritual predecessor, Mutant League Football, BB2 allows players to. The FDA has approved Qinlock for advanced GIST patients who have received prior treatment with three or more kinase inhibitors. Sony has debuted Blood Bowl 2s launch trailer ahead of the games impending release on September 22nd. If you see a patient undergo chemotherapy and radiotherapy: immediately think a secondary cancers have developed as these radiations induce mutations for. In patients with a KIT exon 11 primary mutations, ripretinib demonstrated an objective response rate of 23.9% vs. In the intention-to-treat (ITT) population, ripretinib demonstrated an mPFS of 8.0 months vs.
In patients with a KIT exon 11 primary mutations, ripretinib demonstrated a median PFS (mPFS) of 8.3 months compared to 7.0 months for the sunitinib arm. Patients in the Qinlock arm reported less deterioration in role functioning and better outcomes than sunitinib. In addition, Qinlock had a more favorable safety profile than Pfizer Inc's (NYSE: PFE) Sutent (sunitinib), with fewer Grade 3/4 adverse events. The Journal of Clinical Oncology has published results from Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) INTRIGUE Phase 3 study of Qinlock (ripretinib) for advanced gastrointestinal stromal tumor (GIST) previously treated with Novartis AG's (NYSE: NVS) Gleevec/Glivec (imatinib).Īlthough Qinlock did not offer a statistically significant improvement in progression-free survival (PFS) compared to sunitinib, the drug showed meaningful clinical activity with fewer Grade 3/4 treatment-emergent adverse events and improved tolerability.
0 kommentar(er)
